Atrix and Block Drug Reach Settlement on First of Three Legal Disputes

Apr 24, 2001, 01:00 ET from Atrix Laboratories, Inc.

    FORT COLLINS, Colo., April 24 /PRNewswire Interactive News Release/ --
 Atrix Laboratories, Inc. (Nasdaq: ATRX) announced today that Atrix and
 Block Drug, a wholly owned subsidiary of GlaxoSmithKline, have settled the
 first of three licensing disputes submitted last year.  The settlement
 resolves a pricing dispute over Block's sale of Atrix's periodontal product,
 Atridox(R) and provides payment owed to Atrix for the sale of the product.
     David Bethune, Atrix's chairman and chief executive officer, said,
 "As part of this settlement, we received the payment owed for product sales in
 1999.  We also implemented a new pricing schedule for future purchases in an
 effort to resolve issues of this type in the future.  While we are pleased to
 have this dispute behind us, we intend to pursue resolution of the remaining
 legal issues, including Block's failure to pay Atrix certain milestones
 following approval by the U.S. Food and Drug Administration (FDA) of
 Atrisorb-D(R) guided tissue regeneration barrier product."
 
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer,
 Elan Corporation, Sanofi-Synthelabo, MediGene and the Novartis company --
 Geneva Pharmaceuticals, to use its drug delivery technologies and expertise in
 the development of new products.  Additional information is available on the
 Atrix Laboratories, Inc. Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X82353923
 
 

SOURCE Atrix Laboratories, Inc.
    FORT COLLINS, Colo., April 24 /PRNewswire Interactive News Release/ --
 Atrix Laboratories, Inc. (Nasdaq: ATRX) announced today that Atrix and
 Block Drug, a wholly owned subsidiary of GlaxoSmithKline, have settled the
 first of three licensing disputes submitted last year.  The settlement
 resolves a pricing dispute over Block's sale of Atrix's periodontal product,
 Atridox(R) and provides payment owed to Atrix for the sale of the product.
     David Bethune, Atrix's chairman and chief executive officer, said,
 "As part of this settlement, we received the payment owed for product sales in
 1999.  We also implemented a new pricing schedule for future purchases in an
 effort to resolve issues of this type in the future.  While we are pleased to
 have this dispute behind us, we intend to pursue resolution of the remaining
 legal issues, including Block's failure to pay Atrix certain milestones
 following approval by the U.S. Food and Drug Administration (FDA) of
 Atrisorb-D(R) guided tissue regeneration barrier product."
 
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer,
 Elan Corporation, Sanofi-Synthelabo, MediGene and the Novartis company --
 Geneva Pharmaceuticals, to use its drug delivery technologies and expertise in
 the development of new products.  Additional information is available on the
 Atrix Laboratories, Inc. Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X82353923
 
 SOURCE  Atrix Laboratories, Inc.